Studying Pegylated Liposomes for Cancer Treatment
Author Information
Author(s): Harrington K J, Rowlinson-Busza G, Syrigos K N, Uster P S, Abra R M, Stewart J S W
Primary Institution: ICRF Oncology Unit, Imperial College of Science, Technology and Medicine, Hammersmith Hospital
Hypothesis
The study investigates the biodistribution and pharmacokinetics of pegylated liposomes in a human tumor xenograft model to explore their potential in targeted cancer therapies.
Conclusion
The study found that pegylated liposomes have a stable biodistribution and significant uptake in tumors, suggesting their potential for targeted cancer therapy.
Supporting Evidence
- The maximum tumor uptake of pegylated liposomes was observed at 24 hours.
- Significant uptake was also noted in the liver and spleen.
- Pegylated liposomes showed stability in human serum for up to 10 days.
Takeaway
Researchers looked at how special tiny bubbles called pegylated liposomes move in the body to see if they can help deliver cancer medicine better.
Methodology
Nude mice were injected with pegylated liposomes, and their biodistribution and pharmacokinetics were measured over time.
Participant Demographics
Nude mice were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website